{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.5","value":"69.8"},{"groupId":"OG001","spread":"28.5","value":"67.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"645"}],"units":"Participants"}],"title":"Baseline: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.5","value":"1.5"},{"groupId":"OG001","spread":"22.7","value":"4.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"555"},{"groupId":"OG001","value":"571"}],"units":"Participants"}],"title":"Change at Cycle 5: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.4","value":"3.4"},{"groupId":"OG001","spread":"23.9","value":"5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"495"}],"units":"Participants"}],"title":"Change at Cycle 11: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.1","value":"3.6"},{"groupId":"OG001","spread":"25.8","value":"7.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"409"},{"groupId":"OG001","value":"462"}],"units":"Participants"}],"title":"Change at FU Month 6: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.1","value":"6.2"},{"groupId":"OG001","spread":"27.2","value":"6.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"428"}],"units":"Participants"}],"title":"Change at FU Month 12: Body Image"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.2","value":"51.3"},{"groupId":"OG001","spread":"31.7","value":"50.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"645"}],"units":"Participants"}],"title":"Baseline: FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.3","value":"2.6"},{"groupId":"OG001","spread":"29.9","value":"6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"555"},{"groupId":"OG001","value":"571"}],"units":"Participants"}],"title":"Change at Cycle 5: FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.0","value":"6.3"},{"groupId":"OG001","spread":"31.4","value":"6.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"495"}],"units":"Participants"}],"title":"Change at Cycle 11: FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.5","value":"7.7"},{"groupId":"OG001","spread":"34.6","value":"8.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"409"},{"groupId":"OG001","value":"462"}],"units":"Participants"}],"title":"Change at FU Month 6: FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.1","value":"8.1"},{"groupId":"OG001","spread":"33.0","value":"8.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"428"}],"units":"Participants"}],"title":"Change at FU Month 12: FP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.8","value":"50.9"},{"groupId":"OG001","spread":"28.5","value":"52.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"241"}],"units":"Participants"}],"title":"Baseline: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.4","value":"2.3"},{"groupId":"OG001","spread":"24.6","value":"-1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"172"}],"units":"Participants"}],"title":"Change at Cycle 5: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.5","value":"4.4"},{"groupId":"OG001","spread":"24.5","value":"4.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"title":"Change at Cycle 11: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.1","value":"3.2"},{"groupId":"OG001","spread":"27.5","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"title":"Change at FU Month 6: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.0","value":"5.6"},{"groupId":"OG001","spread":"26.2","value":"1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"title":"Change at FU Month 12: Sexual Enjoyment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.6","value":"20.2"},{"groupId":"OG001","spread":"23.4","value":"22.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"550"},{"groupId":"OG001","value":"564"}],"units":"Participants"}],"title":"Baseline: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.0","value":"3.3"},{"groupId":"OG001","spread":"20.0","value":"2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"456"},{"groupId":"OG001","value":"466"}],"units":"Participants"}],"title":"Change at Cycle 5: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.8","value":"3.1"},{"groupId":"OG001","spread":"20.3","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"393"},{"groupId":"OG001","value":"382"}],"units":"Participants"}],"title":"Change at Cycle 11: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.9","value":"5.1"},{"groupId":"OG001","spread":"23.1","value":"4.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"321"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Change at FU Month 6: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.7","value":"5.9"},{"groupId":"OG001","spread":"22.7","value":"5.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"289"},{"groupId":"OG001","value":"319"}],"units":"Participants"}],"title":"Change at FU Month 12: Sexual Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.1","value":"24.6"},{"groupId":"OG001","spread":"21.0","value":"24.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"645"}],"units":"Participants"}],"title":"Baseline: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.9","value":"-2.8"},{"groupId":"OG001","spread":"23.0","value":"-2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"555"},{"groupId":"OG001","value":"571"}],"units":"Participants"}],"title":"Change at Cycle 5: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.2","value":"-2.6"},{"groupId":"OG001","spread":"24.2","value":"0.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"495"}],"units":"Participants"}],"title":"Change at Cycle 11: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.5","value":"-3.0"},{"groupId":"OG001","spread":"24.2","value":"-1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"409"},{"groupId":"OG001","value":"462"}],"units":"Participants"}],"title":"Change at FU Month 6: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.8","value":"-5.7"},{"groupId":"OG001","spread":"22.6","value":"-1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"428"}],"units":"Participants"}],"title":"Change at FU Month 12: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.1","value":"22.7"},{"groupId":"OG001","spread":"17.9","value":"21.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"645"}],"units":"Participants"}],"title":"Baseline: Breast Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.3","value":"-1.1"},{"groupId":"OG001","spread":"19.1","value":"-1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"555"},{"groupId":"OG001","value":"571"}],"units":"Participants"}],"title":"Change at Cycle 5: Breast Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.8","value":"-3.7"},{"groupId":"OG001","spread":"19.5","value":"-0.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"495"}],"units":"Participants"}],"title":"Change at Cycle 11: Breast Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.0","value":"-6.5"},{"groupId":"OG001","spread":"19.7","value":"-2.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"409"},{"groupId":"OG001","value":"462"}],"units":"Participants"}],"title":"Change at FU Month 6: Breast Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.9","value":"-8.3"},{"groupId":"OG001","spread":"19.2","value":"-3.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"428"}],"units":"Participants"}],"title":"Change at Follow-up Month 12: Breast Function"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.7","value":"16.7"},{"groupId":"OG001","spread":"14.1","value":"16.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"645"}],"units":"Participants"}],"title":"Baseline: Systemic Therapy Side Effects (SE)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.0","value":"0.7"},{"groupId":"OG001","spread":"15.3","value":"5.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"555"},{"groupId":"OG001","value":"571"}],"units":"Participants"}],"title":"Change at Cycle 5: Systemic Therapy SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.2","value":"1.2"},{"groupId":"OG001","spread":"15.4","value":"4.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"495"}],"units":"Participants"}],"title":"Change at Cycle 11: Systemic Therapy SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.9","value":"1.9"},{"groupId":"OG001","spread":"15.3","value":"1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"409"},{"groupId":"OG001","value":"462"}],"units":"Participants"}],"title":"Change at FU Month 6: Systemic Therapy SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.9","value":"1.3"},{"groupId":"OG001","spread":"16.3","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"428"}],"units":"Participants"}],"title":"Change at FU Month 12: Systemic Therapy SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.6","value":"40.3"},{"groupId":"OG001","spread":"38.4","value":"50.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"title":"Baseline: Upset by Hair Loss Item"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.1","value":"-5.1"},{"groupId":"OG001","spread":"39.3","value":"-17.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Change at Cycle 5: Upset by Hair Loss Item"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"45.0","value":"-28.6"},{"groupId":"OG001","spread":"33.9","value":"-14.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Change at Cycle 11: Upset by Hair Loss Item"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.0","value":"-12.0"},{"groupId":"OG001","spread":"42.1","value":"-15.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Change at FU Month 6: Upset by Hair Loss Item"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.5","value":"-2.9"},{"groupId":"OG001","spread":"41.6","value":"-14.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Change at FU Month 12: Upset by Hair Loss Item"}],"denoms":[{"counts":[{"groupId":"OG000","value":"743"},{"groupId":"OG001","value":"743"}],"units":"Participants"}],"description":"EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \\[FP\\]) and four symptom scales (systemic side effects \\[SE\\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Obtained scores are linearly transformed to a score range of 0-100. High score for functional scale indicated high/better level of functioning/healthy functioning. Higher scores for symptom scales represent higher levels of symptoms/problems. For functional scales, positive change from baseline indicated deterioration in QOL and negative change from baseline indicated an improvement in QOL. For symptom scales, positive change from baseline indicated an improvement in QOL and negative change from baseline indicated a deterioration in QOL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received trastuzumab, 6 mg/kg, IV, Q3W, as a maintenance dose for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG000","title":"Trastuzumab"},{"description":"Participants received trastuzumab emtansine, 3.6 mg/kg, IV, Q3W for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG001","title":"Trastuzumab Emtansine"}],"paramType":"MEAN","populationDescription":"ITT population included all participants who were randomized to the study regardless of whether they received any study treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed per timepoint are unique number of participants out of all the assessed participants with data available for analysis at the specified timepoint. Different participants may have contributed data for each timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycles 5 &11, Follow-up (FU) Month 6, FU Month 12 (1 cycle = 21 days)","title":"Change From Baseline in EORTC Quality of Life Questionnaire - Breast Cancer (QLQ-BR23)","type":"SECONDARY","unitOfMeasure":"score on a scale"}